ABIO-FORM 8-K EXEC COMPENSATION AND BOARD OPTIONS

Company

Oruka Therapeutics, Inc.

Filed

February 21, 2017

Period of Report

February 16, 2017

Accession Number

0001564590-17-001838

An 8-K is a current report used to announce material events that shareholders should know about — such as earnings releases, mergers, executive changes, or bankruptcy. Learn more about 8-K filings →